• Mammary gland and prolactin: new data. On the role of prolactin in the genesis of diseases of the mammary glands
To content

Mammary gland and prolactin: new data. On the role of prolactin in the genesis of diseases of the mammary glands

HEALTH OF WOMAN. 2018.1(127): 14–18

Rozhkova N. I., Podzolkova N. M., Ovsyannikova Т. V.
StatusPraesens. Copywriting: Tatiana Ryabinkina, Hilda Simonovskaya

REFERENCES

1. World cancer report 2014. Geneva, WHO. 2014: 630.

2. Zlokachestvennyie novoobrazovaniya v Rossii v 2014 godu (zabolevaemost i smertnost). Pod red. AD Kaprina, BV Starinskogo, GV Petrovoy. M. 2016:250.

3. Kaprin AD, Starinskiy VV, Petrova GV. 2014. Zlokachestvennyie novoobrazovaniya v Rossii v 2012 godu (zabolevaemost i smertnost). M:250.

4. Dobrokachestvennyie displazii molochnyih zhelez: patogeneticheskiy vektor lecheniya. Obzor issledovaniy, klinicheskie rekomendatsii: Informatsionnyiy byulleten. Pod red. EN Andreevoy, NI Rozhkovoy, DA Sokolovoy. M, Redaktsiya zhurnala StatusPraesens. 2016:24.

5. Meditsina molochnoy zhelezyi: Post-reliz i materialyi nauchnoy programmyi III Mezhdistsiplinarnogo foruma. M, Redaktsiya zhurnala StatusPraesens. 2015:24.

6. Bespalov VG, Travina ML. 2015. Fibrozno-kistoznaya bolezn i risk raka molochnoy zhelezyi (obzor literaturyi). Opuholi zhenskoy reproduktivnoy sistemyi 11;4:58–70.

7. Grattan DR. 2015. 60 years of neuroendocrinology: the hypothalamo-prolactin axis. J. Endocrinol. 226;2:t101-t122. PMID: 26101377

8. Veropotvelyan PN. 2011. Vliyanie prolaktina na sostoyanie molochnoy zhelezyi. Meditsinskie aspektyi zdorovya zhenschinyi 43;3–1:29–37.

9. Giperprolaktinemiya: klinika, diagnostika, differentsialnaya diagnostika, metodyi lecheniya: Klinicheskie rekomendatsii. M. 2013:19.

10. Pregravidarnaya podgotovka: Klinicheskiy protokol. Avt.-razrab. VE Radzinskiy i dr. M, Redaktsiya zhurnala StatusPraesens. 2016:80.

11. Das D, Talukdar U, Chisty SJS et al. 2015. Serum prolactin level in patients taking olanzapine. Open J. Psychiatry Allied Sci. 6;1:50–58.

12. Grattan DR. 2015. 60 years of neuroendocrinology: the hypothalamo-prolactin axis. J. Endocrinol. 226;2:101–122. https://doi.org/10.1530/JOE-15-0213; PMid:26101377 PMCid:PMC4515538

13. Meczekalski B, Katulski K, Podfigurna-Stopa A et al. 2016. Spontaneous endogenous pulsatile release of kisspep-tin is temporally coupled with luteinizing hormone in healthy women. Fertil. Steril. 105;5:1345–1350. https://doi.org/10.1016/j.fertnstert.2016.01.029; PMid:26859129

14. Kuznetsova IV, Hovrina EA, Kirpikov AS. 2012. Vosstanovlenie fertilnosti u zhenschin s genitalnyim endometriozom. Akusherstvo i ginekologiya 2:10–15.

15. Artyimuk NV, Kondrateva TA, Tachkova OA. 2009. Printsipyi terapii patsientok s besplodiem i nedostatochnostyu lyuteinovoy fazyi menstrualnogo tsikla. Voprosyi ginekologii, akusherstva i perinatologii 8;4:31–35.

16. Tworoger SS, Eliassen AH, Zhang X et al. 2013. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 73;15:4810–4819. https://doi.org/10.1158/0008-5472.CAN-13-0665; PMid:23783576 PMCid:PMC3738582

17. Semimilliardnyiy zhitel Zemli rodilsya v Rossii. URL: http://www.ntv.ru/novosti/243552

18. Bernichtein S, Touraine P, Goffin V. 2010. New concepts in prolactin biology. J. Endocrinol. 206;1:1–11. https://doi.org/10.1677/JOE-10-0069; PMid:20371569

19. Tworoger SS, Hankinson SE. 2008. Prolactin and breast cancer etiology: An epidemiologic perspective. J. Mammary Gland Biol. Neoplasia. 13;1:41–53.

20. Berinder K, Akre O, Granath F et al. 2011. Cancer risk in hyperprolactinemia patients: A population-based cohort study. Eur. J. Endocrinol. 165;2:209–215. https://doi.org/10.1530/EJE-11-0076; PMid:21602317

21. Veropotvelyan PN. 2012. Sostoyanie molochnyih zhelez u patsientok, stradayuschih besplodiem, posle induktsii ovulyatsii. Meditsinskie aspektyi zdorovya zhenschiny 56;4:32–38.

22. Sotnikova LS i dr. 2011. Sostoyanie gormonalnoy regulyatsii pri fibrozno-kistoznoy mastopatii. Mat i ditya 1:342–346.

23. McHale K, Tomaszewski JE, Puthiyaveettil R et al. 2008. Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod. Pathol. 21;5:565–571. https://doi.org/10.1038/modpathol.2008.7; PMid:18246042

24. Naderi A. 2015. Prolactin-induced protein in breast cancer. Adv. ExP. Med. Biol. 846:189–200. https://doi.org/10.1007/978-3-319-12114-7_8; PMid:25472539

25. Nilsson J, Bjursell G, Kannius-Janson M. 2006. Nuclear Jak2 and transcription factor NF1-C2: a novel mechanism of prolactin signaling in mammary epithelial cells. Mol. Cell Biol. 26;15:5663–5674. https://doi.org/10.1128/MCB.02095-05; PMid:16847321 PMCid:PMC1592781

26. Meléndez Garcia R et al. 2016. Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death. EBioMedicine. 7:35–49. https://doi.org/10.1016/j.ebiom.2016.03.048; PMid:27322457 PMCid:PMC4909382

27. Grattan DR. 2016. The eyes have it! Protective role of prolactin in the retina. EBioMedicine. 8:26–27. https://doi.org/10.1016/j.ebiom.2016.05.030; PMid:27428414 PMCid:PMC4919559

28. Goffin V, Touraine P. 2015. The prolactin receptor as a therapeutic target in human diseases: Browsing new potential indications. Expert Opin. Ther. Targets. 19;9:1229–1244. https://doi.org/10.1517/14728222.2015.1053209; PMid:26063597

29. Garcia RM, Zamarripa DA, Arnold E et al. 2016. Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death. EBioMedicine. 7:35–49. https://doi.org/10.1016/j.ebiom.2016.03.048; PMid:27322457 PMCid:PMC4909382

30. Kit OI, Frantsiyants EM, Bandovkina VA i dr. 2013. Uroven polovyih gormonov i prolaktina v tkani zlokachestvennyh opuholey molochnoy zhelezy u bolnyih raznogo vozrasta. Fundamentalnyie issledovaniya 7:560–564.

31. Damiano JS, Rendahl KG, Karim C et al. 2013. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol. Cancer Ther. 12;3:295–305. https://doi.org/10.1158/1535-7163.MCT-12-0886; PMid:23270929

32. Petersson KJ, Vermeulen AM, Friberg LE. 2013. Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model. AAPS J. 15;2:533–541. https://doi.org/10.1208/s12248-012-9450-6; PMid:23392818 PMCid:PMC3675734

33. Radzinskiy VE, Ordiyants IM. 2013. Vozmozhnosti terapii sochetaniya miomyi matki i dobrokachestvennyih displaziy molochnyih zhelez. Akusherstvo i ginekologiya 4:44–47.

34. Elakad EV i dr. 2011. Sostoyanie gormonalnoy regulyatsii pri fibrozno-kistoznoy mastopatii. Mat i ditya 1:342–346.

35. Die MD van, Burger HG, Teede HJ et al. 2013. Vitex agnus-castus extracts for female reproductive disorders: A systematic review of clinical trials. Planta Med. 79;7:562–575. PMID: 23136064

36. Rapkin AJ, Lewis EI. 2013. Treatment of premenstrual dysphoric disorder. Womens Health (Lond.). 9;6:537–556. PMID: 24161307

37. Halaska M, Beles P, Gorkow C et al. 1999. Treatment of cyclical mastalgia with a solution containing a Vitex agnus cas-tus extract: Results of a placebo-controlled double-blind study. Breast. 8;4:175–181. https://doi.org/10.1054/brst.1999.0039; PMid:14731436

38. Wuttke W, Splitt G, Gorkow C et al. 1997. Treatment of cyclical mastalgia with a medicinal product containing agnus cas-tus: Results of a randomized, placebo-controlled, double blind study. Geburtsh. u. Frauenheilk. 57:569–574. https://doi.org/10.1055/s-2007-1023139

39. Ob utverzhdenii Poryadka okazaniya meditsinskoy pomoschi po profilyu «akusherstvo i ginekologiya (za isklyucheniem ispolzovaniya vspomogatelnyih reproduktivnyih tehnologiy)»: Prikaz Minzdrava RF, 1 noyabrya 2012 g. # 572n.

40. Ob utverzhdenii Poryadka okazaniya meditsinskoy pomoschi naseleniyu po profilyu «onkologiya»: Prikaz Minzdrava RF, 15 noyabrya 2012 g. # 915n.